Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026Unprecedented Efficacy in Both Refractory Undifferentiated
Iovance's cancer medicine showed strong results in patient tests. This hints the company's drug might work better than expected.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.